Array BioPharma, Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Array BioPharma, Inc. - overview

Established

1998

Location

Boulder, CO, US

Primary Industry

Biotechnology

About

Established in 1998 and based in US, Array BioPharma, Inc. operates as a biopharmaceutical company that provides targeted small molecule drugs. The company cooperates with AstraZeneca, Eli Lilly and Genentech, etc. In 2000, it was listed on the NASDAQ.


The company cooperates with Siemens, Fuji Electric and Hager etc. In June 2019, Pfizer Inc. announced to acquire Array BioPharma, Inc. The company provides targeted small molecule drugs for patients with cancer and other high-burden diseases.


Its products include BRAFTOVI® (encorafenib) capsules and MEKTOVI® (binimetinib) tablets. It has over 30 clinical trials, including encorafenib and binimetinib clinical programs.


Current Investors

Amgen Inc., Deerfield Capital Management, Novartis International AG

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Dermatology, Pharmaceutical Research & Development

Website

www.arraybiopharma.com

Verticals

HealthTech, Manufacturing

Company Stage

Acquired

Total Amount Raised

Subscriber access only

Array BioPharma, Inc. - key contacts

NamePositionStart DateEnd DateVcardBio 
Chairman Of The BoardBM
Chairman of the BoardBM

BM Board Member

Want to see more?

Request a demo for full access to this profile

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.